ArticleMolecular and clinical oncology2016
Lateral differences in Ki-67 in breast cancer.
Article in Molecular and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Does Laterality in Breast Cancer still have the Importance to be Studied? A Meta-analysis of Patients with Breast Cancer.Current medicinal chemistry · 2024Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Morphological features of right- and left-sided breast cancer (BC) have been rarely studied. Ki-67 is an independent predictive marker for a local relapse, and for overall and disease-free survival. In previous literature, lateral differences in Ki-67 in BC have not been reported. Using immunohistochemical analysis, the biopsy material of 500 patients was investigated. Four BC parameters were investigated: The expression levels of the estrogen receptor (ER), progesterone receptor (PR), Ki-67 and Her-2-neu. A comparative analysis of Ki-67 in groups with right- and left-sided BC was performed. Lateral differences in Ki-67 in three age groups, ≤49, 50-59 and ≥60 years, were assessed. A higher expression of Ki-67 corresponded with right-sided BC (r=-0.08; P=0.046). Correlation of Ki-67 with the age of the patient was characteristic only for right-sided BC (r=-0.28; P<0.001). The comparative analysis revealed that tumors from patients with right-sided BC aged ≥60 years exhibited a lower Ki-67 index compared with tumors from patients aged ≤49 (P=0.003) and 50-59 years (P=0.000013). In left-sided BC, the Ki-67 in the different age intervals revealed no significant difference. On performing an assessment of lateral differences for the different age intervals, it was established that the Ki-67 index of right-sided BC was significantly higher compared with the left-sided BC in two of the age groups, ≤49 (P=0.038) and 50-59 years (P=0.047). In the ≥60 years group, lateral differences in Ki-67 were not revealed (P=0.4). The analysis of lateral differences in Ki-67 in tumors of various receptor profiles revealed significant differences in Ki-67 of the right- and left-sided BC under ER
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.